Morgan Ebert, Managing Editor

If approved, ibrexafungerp would be the first and only approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent vulvovaginal candidiasis (RVVC).

Genevieve Neal-Perry, MD, PhD, sits down with Contemporary OB/GYN to discuss positive data from a recent phase 3 study evaluating fezolinetant (Astellas) for vasomotor symptoms (VMS).

John Martin, MD, chief medical officer at Butterfly Network, discusses a recent study published in NEJM Evidence, which investigated Butterfly iQ vs a commercial ultrasound machine to detect gestational age.

Contemporary OBGYN® sat down with John Martin, MD, chief medical officer of Butterfly Network Inc., to discuss the Butterfly iQ+, the world's only single-probe, whole-body ultrasound solution.

Perrigo’s HRA Pharma has submitted an application to the US Food and Drug Administration (FDA) for possible future approval of the first-ever OTC birth control pill.

US President Joe Biden signed an executive order Friday protecting nationwide access to abortion and contraception.

Bethany Corbin, Esq., sits down with Contemporary OB/GYN® to discuss the recent Supreme Court ruling overturning Roe v Wade and striking down almost 50 years of abortion precedent.

The United States Supreme Court voted to overturn Roe v Wade on Friday, eliminating the constitutional right to an abortion, and leaving the question of abortion rights to the states.

Data is scare for a comparison of the efficacy of onabotulinumtoxinA for treatment of overactive bladder between patients treated with 1 oral overactive bladder medication vs patients treated with more than 1.

The authors propose that moderate and high physical activity levels tend to be linked with a lower risk of constipation in adults following a meta-analysis of over 3,000 studies.

Health literacy is an integral part of a patient’s ability to make informed health decisions, especially when it comes to chronic pelvic pain (CPP).

The use of dynamic MRI for pelvic organ prolapse is essential for properly counseling patients and interpreting radiographic findings.

Currently approved for the treatment of vulvovaginal candidiasis (VVC), and if the sNDA is approved, ibrexafungerp (Brexafemme; Scynexis) would be the first and only oral non-azole medication for the prevention of recurrent VVC.

Uterine cancer is currently the only cancer type not covered by the World Trade Center (WTC) Health Program.

The US Food and Drug Administration has accepted to review the supplemental New Drug Application for Myfembree for the potential treatment of heavy menstrual bleeding associated with uterine fibroids for up to 2 years.

From COVID-19 to climate change to vulvovaginal candidiasis, the annual meeting offered something for everyone.

Bassem Maximos, MD, MPH, FACOG, discusses 2 recent studies investigating nonhormomal contraceptive gel Phexxi (Evofem Biosciences) for the potential treatment of UTIs and improvement in sexual satisfaction.

Tracy MacNeal, president and CEO of Materna Medical, sits down to discuss the company's recently FDA-cleared Milli Vaginal Dilator for vaginismus and associated dyspareunia, as well as a potential new use for the device currently being studied.

Erin Carey, MD, tackles the different methods for pain management in endometriosis during her presentation at the 2022 American College of Obstetricians & Gynecologists' Annual Clinical & Scientific Meeting.

A study abstract presented at the 2022 ACOG Clinical and Scientific Meeting took a deep dive into Reddit posts to investigate experiences with medication abortion before and during the COVID-19 pandemic.

Catherine Cansino, MD; Andrea Braden, MD; and Lisa Foglia, MD, spoke on how Metrics, wellness models, and management change are essential to advancing diversity, equity, and inclusion (DEI) in obstetrics and gynecology at the 2022 ACOG Annual Clinical & Scientific Meeting.

In this EdTalk, presented at the 2022 American College of Obstetricians & Gynecologists' Annual Clinical & Scientific Meeting, Lisa Foglia, MD; Andrea L. Braden, MD; and Catherine Cansino, MD, MPH, discuss strategies for improving diversity and equity within obstetrics and gynecology.

A recent study presented at the 2022 American College of Obstetricians & Gynecologists' Annual Clinical & Scientific Meeting found that there was neither a decreased nor increased risk for postpartum depression in patients who received hormonal contraception due to insufficient evidence.

Elizabeth Ruzzo, PhD, discusses the findings of a report published by the UNFPA, which found women were abandoning effective methods of contraception due to misinformation.

The US Food and Drug Administration has approved oteseconazole (Vivjoa; Mycovia Pharmaceuticals) to reduce the incidence of recurrent vulvovaginal candidiasis.

A look back at this week's news.

Oklahoma Governor Kevin Stitt signed a bill into law, making performing an abortion a felony, punishable up to 10 years in prison.

In this episode of Pap Talk, Jessica Shepherd, MD, MBA, FACOG, deep dives into the benefits of utilizing radio frequency ablation (RFA) for treatment of uterine fibroids, available RFA devices, and disparities in the condition.

These data build upon previous topline results announced in January 2022.